GLP-1 Receptor Agonists and Long-Term Survival After Spontaneous Intracerebral Hemorrhage in Type 2 Diabetes
Diabetic patients who survived brain bleeds and took GLP-1 drugs showed substantially lower death rates over five years, suggesting a protective pattern worthy of formal testing.
In this large propensity-matched retrospective cohort of 5,420 T2DM patients surviving spontaneous intracerebral hemorrhage, post-event GLP-1 receptor agonist use was associated with a 23% reduction in all-cause mortality at both 2 and 5 years compared to matched non-users. While observational design precludes causal inference, the magnitude and consistency of the signal across follow-up periods is hypothesis-generating and supports prospective investigation.
What the study was
- Study design
- Retrospective cohort study with propensity score matching (1:1)
- Population
- Adults with T2DM who experienced spontaneous intracerebral hemorrhage (sICH) 2018-2024; TriNetX Global Collaborative Network
- Sample size
- 5420
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- World Neurosurgery
Why it surfaced
Novel application of GLP-1 RAs in secondary prevention post-intracerebral hemorrhage; large real-world PSM cohort (n=5420); consistent effect across 2 and 5-year follow-up; fills a gap in metabolic management evidence for sICH survivors; retrospective design caps score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.